These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
114 related items for PubMed ID: 11505748
1. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy]. Pilarska K, Kulig G, Krzystolik Z. Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748 [Abstract] [Full Text] [Related]
2. Urinary glycosaminoglycans in Graves' ophthalmopathy. Kahaly G, Schuler M, Sewell AC, Bernhard G, Beyer J, Krause U. Clin Endocrinol (Oxf); 1990 Jul; 33(1):35-44. PubMed ID: 2401097 [Abstract] [Full Text] [Related]
3. HPLC glycosaminoglycan analysis in patients with Graves' disease. Hansen C, Fraiture B, Rouhi R, Otto E, Förster G, Kahaly G. Clin Sci (Lond); 1997 May; 92(5):511-7. PubMed ID: 9176026 [Abstract] [Full Text] [Related]
4. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Glinoer D, Etienne-Decerf J, Schrooyen M, Sand G, Hoyoux P, Mahieu P, Winand R. Metab Pediatr Syst Ophthalmol (1985); 1988 May; 11(3):133-40. PubMed ID: 3205168 [Abstract] [Full Text] [Related]
5. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy]. Kulig G, Pilarska K, Kulig J, Krzyzanowska-Swiniarska B, Robaczyk M, Baraniak A. Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928 [Abstract] [Full Text] [Related]
6. Determination of urinary mucopolysaccharides in Graves' disease. Ursu H, Dumitrescu C, Bartoc R, Dumitriu L. Endocrinologie; 1984 Dec; 22(4):277-82. PubMed ID: 6240765 [Abstract] [Full Text] [Related]
7. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Martins JR, Furlanetto RP, Oliveira LM, Mendes A, Passerotti CC, Chiamolera MI, Rocha AJ, Manso PG, Nader HB, Dietrich CP, Maciel RM. Clin Endocrinol (Oxf); 2004 Jun; 60(6):726-33. PubMed ID: 15163337 [Abstract] [Full Text] [Related]
8. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Glinoer D, Etienne-Decerf J, Schrooyen M, Sand G, Hoyoux P, Mahieu P, Winand R. Acta Endocrinol (Copenh); 1986 Jan; 111(1):30-8. PubMed ID: 2868602 [Abstract] [Full Text] [Related]
9. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Kung AW, Michon J, Tai KS, Chan FL. Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659 [Abstract] [Full Text] [Related]
11. Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves' ophthalmopathy. Myśliwiec J, Kretowski A, Stepień A, Kinalska I. Immunol Invest; 2004 Feb; 33(1):61-8. PubMed ID: 15015833 [Abstract] [Full Text] [Related]
12. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G. J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448 [Abstract] [Full Text] [Related]
15. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. Nowak M, Siemińska L, Karpe J, Marek B, Kos-Kudła B, Kajdaniuk D. J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519 [Abstract] [Full Text] [Related]
16. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy]. Myśliwiec J, Kretowski A, Topolska J, Stepień A, Kinalska I. Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893 [Abstract] [Full Text] [Related]
17. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression. Popławska-Kita A, Mierzejewska-Iwanowska B, Szelachowska M, Siewko K, Nikołajuk A, Kinalska I, Górska M. Diabetes Metab Res Rev; 2008 Aug; 24(4):310-7. PubMed ID: 18273859 [Abstract] [Full Text] [Related]
18. Urinary excretion of glycosaminoglycans in patients with postmenopausal osteoporosis. Todorova S, Antov G, Levi S, Michailova A, Topalova N, Toneva Z. Horm Metab Res; 1992 Dec; 24(12):585-7. PubMed ID: 1478619 [Abstract] [Full Text] [Related]
19. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy]. Modelska-Ziółkiewicz A, Gembicki M, Bednarek J, Sowiński J. Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175 [Abstract] [Full Text] [Related]
20. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy. Tsujino K, Hirota S, Hagiwara M, Fukada S, Takada Y, Hishikawa Y, Kono M, Abe M. Int J Radiat Oncol Biol Phys; 2000 Oct 01; 48(3):857-64. PubMed ID: 11020584 [Abstract] [Full Text] [Related] Page: [Next] [New Search]